{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T10:55:59Z","timestamp":1781261759567,"version":"3.54.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,12,28]],"date-time":"2016-12-28T00:00:00Z","timestamp":1482883200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s10067-016-3527-z","type":"journal-article","created":{"date-parts":[[2016,12,28]],"date-time":"2016-12-28T14:28:18Z","timestamp":1482935298000},"page":"2307-2318","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases"],"prefix":"10.1007","volume":"36","author":[{"given":"Claudia","family":"Fabiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen","family":"Sota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Tosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,28]]},"reference":[{"key":"3527_CR1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8518-3","volume":"49","author":"E Generali","year":"2015","unstructured":"Generali E, Cantarini L, Selmi C (2015) Ocular involvement in systemic autoimmune diseases. Clin Rev Allergy Immunol 49:263\u2013270","journal-title":"Clin Rev Allergy Immunol"},{"key":"3527_CR2","first-page":"991","volume":"66","author":"SJ Patel","year":"2002","unstructured":"Patel SJ, Lundy DC (2002) Ocular manifestations of autoimmune disease. Am Fam Physician 66:991\u2013998","journal-title":"Am Fam Physician"},{"key":"3527_CR3","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.4049\/jimmunol.172.6.3736","volume":"172","author":"PS Biswas","year":"2004","unstructured":"Biswas PS, Banerjee K, Kim B, Rouse BT (2004) Mice transgenic for IL-1 receptor antagonist protein are resistant to herpetic stromal keratitis: possible role for IL-1 in herpetic stromal keratitis pathogenesis. J Immunol 172:3736\u20133744","journal-title":"J Immunol"},{"key":"3527_CR4","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1038\/gt.2008.109","volume":"15","author":"P Trittibach","year":"2008","unstructured":"Trittibach P, Barker SE, Broderick CA, Natkunarajah M, Duran Y, Robbie SJ, Bainbridge JW, Smith AJ, Sarra GM, Dick AD, Ali RR (2008) Lentiviral-vector-mediated expression of murine IL-1 receptor antagonist or IL-10 reduces the severity of endotoxin-induced uveitis. Gene Ther 15:1478\u20131488","journal-title":"Gene Ther"},{"key":"3527_CR5","first-page":"1542","volume":"15","author":"ML Tsai","year":"2009","unstructured":"Tsai ML, Horng CT, Chen SL, Xiao X, Wang CH, Tsao YP (2009) Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist. Mol Vis 15:1542\u20131552","journal-title":"Mol Vis"},{"key":"3527_CR6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, Simonini G, Borsari G, Caso F, Lucherini OM, Frediani B, Bertoldi I, Punzi L, Galeazzi M, Cimaz R (2015a) Anakinra treatment in drug-resistant Beh\u00e7et's disease: a case series. Clin Rheumatol 34:1293\u20131301","journal-title":"Clin Rheumatol"},{"key":"3527_CR7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jamaophthalmol.2013.195","volume":"131","author":"F Amparo","year":"2013","unstructured":"Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, Jurkunas U, Schaumberg DA, Dana R (2013) Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol 131:715\u2013723","journal-title":"JAMA Ophthalmol"},{"key":"3527_CR8","doi-asserted-by":"publisher","unstructured":"Goldstein MH, Martel JR, Sall K, Goldberg DF, Abrams M, Rubin J, Sheppard J, Tauber J, Korenfeld M, Agahigian J, Durham TA, Furfine E (2016) Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease. Eye Contact Lens. doi: 10.1097\/ICL.0000000000000276","DOI":"10.1097\/ICL.0000000000000276"},{"key":"3527_CR9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","volume":"25","author":"CA Dinarello","year":"2013","unstructured":"Dinarello CA, van der Meer JW (2013) Treating inflammation by blocking interleukin-1 in humans. Semin Immunol 25:469\u2013484","journal-title":"Semin Immunol"},{"key":"3527_CR10","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.exer.2015.06.018","volume":"138","author":"B Zhao","year":"2015","unstructured":"Zhao B, Chen W, Jiang R, Zhang R, Wang Y, Wang L, Gordon L, Chen L (2015) Expression profile of IL-1 family cytokines in aqueous humor and sera of patients with HLA-B27 associated anterior uveitis and idiopathic anterior uveitis. Exp Eye Res 138:80\u201386","journal-title":"Exp Eye Res"},{"key":"3527_CR11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4049\/jimmunol.1502080","volume":"196","author":"CK Wan","year":"2016","unstructured":"Wan CK, He C, Sun L, Egwuagu CE, Leonard WJ (2016) Cutting edge: IL-1 receptor signaling is critical for the development of autoimmune uveitis. J Immunol 196:543\u2013546","journal-title":"J Immunol"},{"key":"3527_CR12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/09273940802710705","volume":"17","author":"JL Olson","year":"2009","unstructured":"Olson JL, Courtney RJ, Rouhani B, Mandava N, Dinarello CA (2009) Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model. Ocul Immunol Inflamm 17:195\u2013200","journal-title":"Ocul Immunol Inflamm"},{"key":"3527_CR13","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/art.22966","volume":"56","author":"JI Ar\u00f3stegui","year":"2007","unstructured":"Ar\u00f3stegui JI, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P, Garc\u00eda-Consuegra J, Naranjo A, Ramos E, de Paz P, Rius J, Plaza S, Yag\u00fce J (2007) NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1blockade in a Spanish cohort. Arthritis Rheum 56:3805\u20133813","journal-title":"Arthritis Rheum"},{"key":"3527_CR14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.37776","volume":"65","author":"G Simonini","year":"2013","unstructured":"Simonini G, Xu Z, Caputo R, De Libero C, Pagnini I, Pascual V, Cimaz R (2013) Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum 65:513\u2013518","journal-title":"Arthritis Rheum"},{"key":"3527_CR15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bjo.2006.0101477","volume":"91","author":"SC Teoh","year":"2007","unstructured":"Teoh SC, Sharma S, Hogan A, Lee R, Ramanan AV, Dick AD (2007) Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome. Br J Ophthalmol 91:263\u2013264","journal-title":"Br J Ophthalmol"},{"key":"3527_CR16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12348-015-0065-9","volume":"5","author":"M Hirano","year":"2015","unstructured":"Hirano M, Seguchi J, Yamamura M, Narita A, Okanobu H, Nishikomori R, Heike T, Hosokawa M, Morizane Y, Shiraga F (2015) Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study. J Ophthalmic Inflamm Infect 5:34","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"3527_CR17","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"A G\u00fcl","year":"2012","unstructured":"G\u00fcl A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, Scannon P, Solinger A (2012) Interleukin-1\u03b2-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study. Ann Rheum Dis 71:563\u2013566","journal-title":"Ann Rheum Dis"},{"key":"3527_CR18","first-page":"1","volume":"30","author":"I Tugal-Tutkun","year":"2016","unstructured":"Tugal-Tutkun I, Kadayifcilar S, Khairallah M, Lee SC, Ozdal P, \u00d6zyazgan Y, Song JH, Yu HG, Lehner V, de Cordoue A, Bernard O, G\u00fcl A (2016) Safety and efficacy of gevokizumab in patients with Beh\u00e7et's disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm 30:1\u20139","journal-title":"Ocul Immunol Inflamm"},{"key":"3527_CR19","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","volume":"71","author":"S Ugurlu","year":"2012","unstructured":"Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Beh\u00e7et's syndrome with refractory eye disease. Ann Rheum Dis 71:1589\u20131591","journal-title":"Ann Rheum Dis"},{"key":"3527_CR20","first-page":"152","volume":"31","author":"G Emmi","year":"2013","unstructured":"Emmi G, Silvestri E, Cameli AM, Bacherini D, Vannozzi L, Squatrito D, Emmi L (2013) Anakinra for resistant Beh\u00e7et uveitis: why not? Clin Exp Rheumatol 31:152\u2013153","journal-title":"Clin Exp Rheumatol"},{"issue":"4 Suppl 84","key":"3527_CR21","first-page":"S171","volume":"32","author":"F Caso","year":"2014","unstructured":"Caso F, Rigante D, Vitale A, Lucherini OM, Cantarini L (2014) Efficacy of anakinra in refractory Beh\u00e7et's disease sacroiliitis. Clin Exp Rheumatol 32(4 Suppl 84):S171","journal-title":"Clin Exp Rheumatol"},{"key":"3527_CR22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L, Franceschini R, Lucherini OM, Cantarini L (2014) Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et's disease: a case series. Dermatology 228:211\u2013214","journal-title":"Dermatology"},{"issue":"4 Suppl 84","key":"3527_CR23","first-page":"S172","volume":"32","author":"G Emmi","year":"2014","unstructured":"Emmi G, Silvestri E, Ciucciarelli L, Squatrito D, Emmi L (2014) Reply: anti-IL1 blocking agents in drug-resistant Beh\u00e7et's syndrome: our little case series. Clin Exp Rheumatol 32(4 Suppl 84):S172","journal-title":"Clin Exp Rheumatol"},{"key":"3527_CR24","doi-asserted-by":"publisher","unstructured":"Emmi G, Silvestri E, Squatrito D, Vitale A, Bacherini D, Vannozzi L, Emmi L, D'Elios MM, Cantarini L, Prisco D (2016b) Long-term efficacy and safety of anakinra in a patient with Beh\u00e7et's disease and concomitant tuberculosis infection. Int J Dermatol. doi: 10.1111\/ijd.13337","DOI":"10.1111\/ijd.13337"},{"key":"3527_CR25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","volume":"35","author":"G Emmi","year":"2016","unstructured":"Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, Olivieri I, Goldoni M, Vitale A, Silvestri E, Prisco D, Lapadula G, Galeazzi M, Iannone F, Cantarini L (2016a) Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et's disease: a multicenter retrospective study. Clin Rheumatol 35:1281\u20131286","journal-title":"Clin Rheumatol"},{"key":"3527_CR26","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.3899\/jrheum.160064","volume":"43","author":"A Brambilla","year":"2016","unstructured":"Brambilla A, Caputo R, Cimaz R, Simonini G (2016) Canakinumab for childhood sight-threatening refractory uveitis: a case series. J Rheumatol 43:1445\u20131447","journal-title":"J Rheumatol"},{"key":"3527_CR27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/ICL.0000000000000152","volume":"41","author":"MH Goldstein","year":"2015","unstructured":"Goldstein MH, Tubridy KL, Agahigian J, Furfine E, Magill M, Kovalchin J, Golden K, Zarbis-Papastoitsis G, Soong F, Salapatek AM, Sternberg G, Celniker A (2015) A phase 2 exploratory study of a novel interleukin-1 receptor inhibitor (EBI-005) in the treatment of moderate-to-severe allergic conjunctivitis. Eye Contact Lens 41:145\u2013155","journal-title":"Eye Contact Lens"},{"key":"3527_CR28","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/rheumatology\/kem052","volume":"46","author":"C Botsios","year":"2007","unstructured":"Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L (2007) Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases Rheumatology (Oxford) 46:1042\u20131043","journal-title":"Report of two cases Rheumatology (Oxford)"},{"key":"3527_CR29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ajo.2016.09.017","volume":"172","author":"JE Knickelbein","year":"2016","unstructured":"Knickelbein JE, Tucker WR, Bhatt N, Armbrust K, Valent D, Obiyor D, Nussenblatt RB, Sen HN (2016) Gevokizumab in the treatment of autoimmune, non-necrotizing, anterior scleritis: results of a phase I\/II clinical trial. Am J Ophthalmol 172:104\u2013110","journal-title":"Am J Ophthalmol"},{"key":"3527_CR30","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/rheumatology\/kel399","volume":"46","author":"T Lequerr\u00e9","year":"2007","unstructured":"Lequerr\u00e9 T, Vittecoq O, Saugier-Veber P, Goldenberg A, Patoz P, Fr\u00e9bourg T, Le Lo\u00ebt X (2007) A cryopyrin-associated periodic syndrome with joint destruction. Rheumatology (Oxford) 46:709\u2013701","journal-title":"Rheumatology (Oxford)"},{"key":"3527_CR31","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcjo.2014.01.007","volume":"49","author":"L Espandar","year":"2014","unstructured":"Espandar L, Boehlke CS, Kelly MP (2014) First report of keratitis in familial cold autoinflammatory syndrome. Can J Ophthalmol 49:304\u2013306","journal-title":"Can J Ophthalmol"},{"key":"3527_CR32","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/rheumatology\/ket486","volume":"53","author":"N Alejandre","year":"2014","unstructured":"Alejandre N, Ruiz-Palacios A, Garc\u00eda-Aparicio AM, Blanco-Kelly F, Berm\u00fadez S, Fern\u00e1ndez-Sanz G, Romero FI, Ar\u00f3stegui JI, Ayuso C, Jim\u00e9nez-Alfaro I, Herrero-Beaumont G, S\u00e1nchez-Pernaute O (2014) Description of a new family with cryopyrin-associated periodic syndrome: risk of visual loss in patients bearing the R260W mutation. Rheumatology (Oxford) 53:1095\u20131099","journal-title":"Rheumatology (Oxford)"},{"key":"3527_CR33","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12348-010-0018-2","volume":"1","author":"C Terrada","year":"2011","unstructured":"Terrada C, Neven B, Boddaert N, Souied EH, Prieur AM, Quartier P, Lehoang P, Bodaghi B (2011) Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra. J Ophthalmic Inflamm Infect 1:133\u2013136","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"3527_CR34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ajo.2012.01.034","volume":"154","author":"A Okanobo","year":"2012","unstructured":"Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R (2012) Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol 154:63\u201371","journal-title":"Am J Ophthalmol"},{"key":"3527_CR35","first-page":"1957","volume":"19","author":"T Vijmasi","year":"2013","unstructured":"Vijmasi T, Chen FY, Chen YT, Gallup M, McNamara N (2013) Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. Mol Vis 19:1957\u20131965","journal-title":"Mol Vis"},{"key":"3527_CR36","doi-asserted-by":"crossref","first-page":"e60714","DOI":"10.1371\/journal.pone.0060714","volume":"8","author":"J Yuan","year":"2013","unstructured":"Yuan J, Liu Y, Huang W, Zhou S, Ling S, Chen J (2013) The experimental treatment of corneal graft rejection with the interleukin-1 receptor antagonist (IL-1ra) gene. PLoS One 8:e60714","journal-title":"PLoS One"},{"key":"3527_CR37","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1016\/j.transproceed.2004.10.075","volume":"36","author":"Y Jie","year":"2004","unstructured":"Jie Y, Pan Z, Chen Y, Wei Y, Zhang W, Xu L, Wu Y, Peng H (2004) SEB combined with IL-1ra could prolong the survival of the rat allografts in high-risk corneal transplantation. Transplant Proc 36:3267\u20133271","journal-title":"Transplant Proc"},{"key":"3527_CR38","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/ATVBAHA.113.301331","volume":"33","author":"JC Rivera","year":"2013","unstructured":"Rivera JC, Sitaras N, Noueihed B, Hamel D, Madaan A, Zhou T, Honor\u00e9 JC, Quiniou C, Joyal JS, Hardy P, Sennlaub F, Lubell W, Chemtob S (2013) Microglia and interleukin-1\u03b2 in ischemic retinopathy elicit microvascular degeneration through neuronal semaphorin-3A. Arterioscler Thromb Vasc Biol 33:1881\u20131891","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3527_CR39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.pop.2015.05.003","volume":"42","author":"JP Dunn","year":"2015","unstructured":"Dunn JP (2015) Uveitis. Prim Care 42:305\u2013323","journal-title":"Prim Care"},{"key":"3527_CR40","first-page":"1","volume":"14","author":"D Rigante","year":"2010","unstructured":"Rigante D (2010) The protean visage of systemic autoinflammatory syndromes: a challenge for inter-professional collaboration. Eur Rev Med Pharmacol Sci 14:1\u201318","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3527_CR41","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1002\/art.10688","volume":"46","author":"I Aksentijevich","year":"2002","unstructured":"Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, Stein L, Russo R, Goldsmith D, Dent P, Rosenberg HF, Austin F, Remmers EF, Balow JE Jr, Rosenzweig S, Komarow H, Shoham NG, Wood G, Jones J, Mangra N, Carrero H, Adams BS, Moore TL, Schikler K, Hoffman H, Lovell DJ, Lipnick R, Barron K, O'Shea JJ, Kastner DL, Goldbach-Mansky R (2002) De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 46:3340\u20133348","journal-title":"Arthritis Rheum"},{"key":"3527_CR42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00296-009-0939-y","volume":"30","author":"D Rigante","year":"2010","unstructured":"Rigante D, Stabile A, Minnella A, Avallone L, Ziccardi L, Bersani G, Stifano G, Compagnone A, Falsini B (2010) Post-inflammatory retinal dystrophy in CINCA syndrome. Rheumatol Int 30:389\u2013393","journal-title":"Rheumatol Int"},{"key":"3527_CR43","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1136\/annrheumdis-2013-204877","volume":"74","author":"CH Sibley","year":"2015","unstructured":"Sibley CH, Chioato A, Felix S, Colin L, Chakraborty A, Plass N, Rodriguez-Smith J, Brewer C, King K, Zalewski C, Kim HJ, Bishop R, Abrams K, Stone D, Chapelle D, Kost B, Snyder C, Butman JA, Wesley R, Goldbach-Mansky R (2015) A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann Rheum Dis 74:1714\u20131719","journal-title":"Ann Rheum Dis"},{"key":"3527_CR44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00281-015-0502-8","volume":"37","author":"A G\u00fcl","year":"2015","unstructured":"G\u00fcl A (2015) Pathogenesis of Beh\u00e7et's disease: autoinflammatory features and beyond. Semin Immunopathol 37:413\u2013418","journal-title":"Semin Immunopathol"},{"key":"3527_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","volume":"14","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Caso F, Costa L, Iannone F, Lapadula G, Anelli MG, Franceschini R, Menicacci C, Galeazzi M, Selmi C, Rigante D (2015b) Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et's disease. Autoimmun Rev 14:1\u20139","journal-title":"Autoimmun Rev"},{"key":"3527_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-016-3506-4","author":"C Fabiani","year":"2016","unstructured":"Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Gentileschi S, Bacherini D, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L (2016) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease related uveitis: a multicenter retrospective observational study. Clin Rheumatol. doi: 10.1007\/s10067-016-3506-4","journal-title":"Clin Rheumatol"},{"key":"3527_CR47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.intimp.2014.06.041","volume":"22","author":"R Zhao","year":"2014","unstructured":"Zhao R, Zhou H, Zhang J, Liu X, Su SB (2014) Interleukin-1\u03b2 promotes the induction of retinal autoimmune disease. Int Immunopharmacol 22:285\u2013292","journal-title":"Int Immunopharmacol"},{"key":"3527_CR48","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1128\/IAI.70.4.2187-2197.2002","volume":"70","author":"A Thakur","year":"2002","unstructured":"Thakur A, Xue M, Stapleton F, Lloyd AR, Wakefield D, Willcox MD (2002) Balance of pro- and anti-inflammatory cytokines correlates with outcome of acute experimental Pseudomonas Aeruginosa keratitis. Infect Immun 70:2187\u20132197","journal-title":"Infect Immun"},{"key":"3527_CR49","doi-asserted-by":"crossref","unstructured":"The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 5(2):75\u201392","DOI":"10.1016\/S1542-0124(12)70081-2"},{"key":"3527_CR50","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/archophthalmol.2011.364","volume":"130","author":"W Stevenson","year":"2012","unstructured":"Stevenson W, Chauhan SK, Dana R (2012) Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 130:90\u2013100","journal-title":"Arch Ophthalmol"},{"key":"3527_CR51","first-page":"2283","volume":"42","author":"A Solomon","year":"2001","unstructured":"Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC (2001) Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 42:2283\u20132292","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3527_CR52","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.exer.2008.11.019","volume":"88","author":"M Heur","year":"2009","unstructured":"Heur M, Chaurasia SS, Wilson SE (2009) Expression of interleukin-1 receptor antagonist in human cornea. Exp Eye Res 88:992\u2013994","journal-title":"Exp Eye Res"},{"key":"3527_CR53","first-page":"862","volume":"16","author":"A Enr\u00edquez-de-Salamanca","year":"2010","unstructured":"Enr\u00edquez-de-Salamanca A, Castellanos E, Stern ME, Fern\u00e1ndez I, Carre\u00f1o E, Garc\u00eda-V\u00e1zquez C, Herreras JM, Calonge M (2010) Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis 16:862\u2013873","journal-title":"Mol Vis"},{"key":"3527_CR54","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1073\/pnas.1217996110","volume":"110","author":"J Hou","year":"2013","unstructured":"Hou J, Townson SA, Kovalchin JT, Masci A, Kiner O, Shu Y, King BM, Schirmer E, Golden K, Thomas C, Garcia KC, Zarbis-Papastoitsis G, Furfine ES, Barnes TM (2013) Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci U S A 110:3913\u20133918","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3527_CR55","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.4049\/jimmunol.152.11.5532","volume":"152","author":"RI Fox","year":"1994","unstructured":"Fox RI, Kang HI, Ando D, Abrams J, Pisa E (1994) Cytokine mRNA expression in salivary gland biopsies of Sj\u00f6gren's syndrome. J Immunol 152:5532\u20135539","journal-title":"J Immunol"},{"key":"3527_CR56","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/ard.62.4.359","volume":"62","author":"P Willeke","year":"2003","unstructured":"Willeke P, Schotte H, Schl\u00fcter B, Erren M, Becker H, Dyong A, Mickholz E, Domschke W, Gaubitz M (2003) Interleukin-1beta and tumour necrosis factor-alpha secreting cells are increased in the peripheral blood of patients with primary Sj\u00f6gren's syndrome. Ann Rheum Dis 62:359\u2013362","journal-title":"Ann Rheum Dis"},{"key":"3527_CR57","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/joim.12115","volume":"274","author":"C Baldini","year":"2013","unstructured":"Baldini C, Rossi C, Ferro F, Santini E, Seccia V, Donati V, Solini A (2013) The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sj\u00f6gren's syndrome. J Intern Med 274:480\u2013489","journal-title":"J Intern Med"},{"key":"3527_CR58","first-page":"354","volume":"32","author":"B Xie","year":"2014","unstructured":"Xie B, Chen Y, Zhang S, Wu X, Zhang Z, Peng Y, Huang X (2014) The expression of P2X7 receptors on peripheral blood mononuclear cells in patients with primary Sj\u00f6gren's syndrome and its correlation with anxiety and depression. Clin Exp Rheumatol 32:354\u2013360","journal-title":"Clin Exp Rheumatol"},{"key":"3527_CR59","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/cei.12644","volume":"181","author":"F Ciccia","year":"2015","unstructured":"Ciccia F, Accardo-Palumbo A, Alessandro R, Alessandri C, Priori R, Guggino G, Raimondo S, Carubbi F, Valesini G, Giacomelli R, Rizzo A, Triolo G (2015) Interleukin-36\u03b1 axis is modulated in patients with primary Sj\u00f6gren's syndrome. Clin Exp Immunol 181:230\u2013238","journal-title":"Clin Exp Immunol"},{"key":"3527_CR60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ajo.2015.09.039","volume":"161","author":"A L\u00f3pez-Miguel","year":"2016","unstructured":"L\u00f3pez-Miguel A, Tes\u00f3n M, Mart\u00edn-Monta\u00f1ez V, Enr\u00edquez-de-Salamanca A, Stern ME, Gonz\u00e1lez-Garc\u00eda MJ, Calonge M (2016) Clinical and molecular inflammatory response in Sj\u00f6gren syndrome-associated dry eye patients under desiccating stress. Am J Ophthalmol 161:133\u201341.e1-2","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 1","key":"3527_CR61","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.2119\/molmed.2014.00232","volume":"20","author":"CA Dinarello","year":"2014","unstructured":"Dinarello CA (2014) An expanding role for interleukin-1 blockade from gout to cancer. Mol Med 20(Suppl 1):S43\u2013S58","journal-title":"Mol Med"},{"key":"3527_CR62","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/IAE.0000000000000701","volume":"36","author":"M Stahel","year":"2016","unstructured":"Stahel M, Becker M, Graf N, Michels S (2016) Systemic interleukin 1\u03b2 inhibition in proliferative diabetic retinopathy: a prospective open-label study using canakinumab. Retina 36:385\u2013391","journal-title":"Retina"},{"key":"3527_CR63","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1167\/iovs.08-2732","volume":"50","author":"P Lu","year":"2009","unstructured":"Lu P, Li L, Liu G, Zhang X, Mukaida N (2009) Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist. Invest Ophthalmol Vis Sci 50:4761\u20134768","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3527_CR64","first-page":"4203","volume":"41","author":"J Yamada","year":"2000","unstructured":"Yamada J, Zhu SN, Streilein JW, Dana MR (2000) Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation. Invest Ophthalmol Vis Sci 41:4203\u20134208","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3527_CR65","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1167\/iovs.12-11483","volume":"54","author":"S Sugita","year":"2013","unstructured":"Sugita S, Kawazoe Y, Imai A, Usui Y, Iwakura Y, Isoda K, Ito M, Mochizuki M (2013) Mature dendritic cell suppression by IL-1 receptor antagonist on retinal pigment epithelium cells. Invest Ophthalmol Vis Sci 54:3240\u20133249","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3527_CR66","doi-asserted-by":"crossref","first-page":"e0144460","DOI":"10.1371\/journal.pone.0144460","volume":"10","author":"Y Liu","year":"2015","unstructured":"Liu Y, Kimura K, Orita T, Sonoda KH (2015) Necrosis-induced sterile inflammation mediated by interleukin-1\u03b1 in retinal pigment epithelial cells. PLoS One 10:e0144460","journal-title":"PLoS One"},{"key":"3527_CR67","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.ophtha.2012.07.008","volume":"120","author":"N Yoshida","year":"2013","unstructured":"Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, Enaida H, Ishibashi T (2013a) Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 120:e5\u201312","journal-title":"Ophthalmology"},{"key":"3527_CR68","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ophtha.2012.07.006","volume":"120","author":"N Yoshida","year":"2013","unstructured":"Yoshida N, Ikeda Y, Notomi S, Ishikawa K, Murakami Y, Hisatomi T, Enaida H, Ishibashi T (2013b) Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 120:100\u2013105","journal-title":"Ophthalmology"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3527-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3527-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3527-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T13:37:36Z","timestamp":1692625056000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3527-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,28]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["3527"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3527-z","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,28]]}}}